-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $20

Benzinga·12/05/2025 15:22:37
語音播報
Morgan Stanley analyst Sean Laaman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Overweight rating and announces Price Target of $20.